This single center, open-label, non-randomized, one-treatment, one-period study will evaluate the metabolic profile and the safety of a single oral radiolabeled dose of dalcetrapib in male healthy volunteers.

Inclusion Criteria:

• Healthy male subjects, 45 to 65 years of age inclusive
• Body mass index (BMI) between 18 and 32 kg/m2 inclusive

Exclusion Criteria:

• Any concomitant disease or ongoing condition that in the investigator's opinion could interfere with the study or could pose an unacceptable risk to the subject
• Clinically significant abnormal laboratory values
• Infrequent bowel movements (e.g. less than one movement per 24 h on average)
• An intent to father children within 3 months of dosing
• Any external or internal radiotherapy with open (nuclear medicine) or sealed sources (brachy therapy)
• External irradiation (radiological examination) or internal radiation (diagnostic nuclear medicine procedure) within one year before study drug dosing; dental radiography and plain X-rays of the extremities are allowed before dosing